Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall survival (OS)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	NPJ precision oncology Jg. 9; H. 1; S. 24 - 7
Hauptverfasser:	Patel, Sandip P., Cano-Linson, Eleanor, Chae, Young Kwang, Schokrpur, Shiruyeh, Lao, Christopher D., Powers, Benjamin C., Victor, Adrienne I., Onitilo, Adedayo A., Shin, Sarah, Takebe, Naoko, Threlkel, Sara, McLeod, Christine M., Chen, Helen X., Sharon, Elad, Othus, Megan, Ryan, Christopher W., Blanke, Charles D., Kurzrock, Razelle
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 24.01.2025 Nature Publishing Group Nature Portfolio
Schlagworte:	692/308/409 692/4028/67/1813/1349 Cancer Research Diarrhea Gene Therapy Human Genetics Immunotherapy Internal Medicine Lung cancer Medical research Medicine Medicine & Public Health Metastasis Monoclonal antibodies Oncology Patients Skin cancer Targeted cancer therapy Toxicity Tumors
ISSN:	2397-768X, 2397-768X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!